JP2021518414A5 - - Google Patents

Info

Publication number
JP2021518414A5
JP2021518414A5 JP2020550823A JP2020550823A JP2021518414A5 JP 2021518414 A5 JP2021518414 A5 JP 2021518414A5 JP 2020550823 A JP2020550823 A JP 2020550823A JP 2020550823 A JP2020550823 A JP 2020550823A JP 2021518414 A5 JP2021518414 A5 JP 2021518414A5
Authority
JP
Japan
Prior art keywords
composition according
bacterial strain
cells
composition
heterologous antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020550823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518414A (ja
Filing date
Publication date
Priority claimed from GBGB1804384.4A external-priority patent/GB201804384D0/en
Priority claimed from GBGB1809953.1A external-priority patent/GB201809953D0/en
Priority claimed from GBGB1811900.8A external-priority patent/GB201811900D0/en
Priority claimed from GBGB1812378.6A external-priority patent/GB201812378D0/en
Priority claimed from GBGB1813444.5A external-priority patent/GB201813444D0/en
Priority claimed from GBGB1813423.9A external-priority patent/GB201813423D0/en
Priority claimed from GBGB1816834.4A external-priority patent/GB201816834D0/en
Priority claimed from GBGB1817641.2A external-priority patent/GB201817641D0/en
Priority claimed from GBGB1901199.8A external-priority patent/GB201901199D0/en
Priority claimed from GBGB1901218.6A external-priority patent/GB201901218D0/en
Priority claimed from GBGB1901993.4A external-priority patent/GB201901993D0/en
Priority claimed from GBGB1901992.6A external-priority patent/GB201901992D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/056894 external-priority patent/WO2019180051A1/en
Publication of JP2021518414A publication Critical patent/JP2021518414A/ja
Publication of JP2021518414A5 publication Critical patent/JP2021518414A5/ja
Pending legal-status Critical Current

Links

JP2020550823A 2018-03-19 2019-03-19 細菌株を含む組成物 Pending JP2021518414A (ja)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
GBGB1804384.4A GB201804384D0 (en) 2018-03-19 2018-03-19 Compositions
GB1804384.4 2018-03-19
EP18178350 2018-06-18
GBGB1809953.1A GB201809953D0 (en) 2018-06-18 2018-06-18 Compositions
EP18178350.7 2018-06-18
GB1809953.1 2018-06-18
GBGB1811900.8A GB201811900D0 (en) 2018-07-20 2018-07-20 Compositions comprising bacterial strains
GB1811900.8 2018-07-20
GBGB1812378.6A GB201812378D0 (en) 2018-07-30 2018-07-30 Compositions comprising bacterial strains
GB1812378.6 2018-07-30
GB1813444.5 2018-08-17
GB1813423.9 2018-08-17
GBGB1813423.9A GB201813423D0 (en) 2018-08-17 2018-08-17 Compositions comprising bacterial strains
GBGB1813444.5A GB201813444D0 (en) 2018-08-17 2018-08-17 Compositions
GB1816834.4 2018-10-16
GBGB1816834.4A GB201816834D0 (en) 2018-10-16 2018-10-16 Compositions
GB1817641.2 2018-10-29
GBGB1817641.2A GB201817641D0 (en) 2018-10-29 2018-10-29 Compositions comprising bacterial strains
GBGB1901199.8A GB201901199D0 (en) 2019-01-29 2019-01-29 Compositions comprising bacterial strains
GB1901199.8 2019-01-29
GB1901218.6 2019-01-29
GBGB1901218.6A GB201901218D0 (en) 2019-01-29 2019-01-29 Compositions
GBGB1901993.4A GB201901993D0 (en) 2019-02-13 2019-02-13 Compositions
GB1901993.4 2019-02-13
GBGB1901992.6A GB201901992D0 (en) 2019-02-13 2019-02-13 Compositions comprising bacterial strains
GB1901992.6 2019-02-13
PCT/EP2019/056894 WO2019180051A1 (en) 2018-03-19 2019-03-19 Compositions comprising bacterial strains

Publications (2)

Publication Number Publication Date
JP2021518414A JP2021518414A (ja) 2021-08-02
JP2021518414A5 true JP2021518414A5 (cg-RX-API-DMAC7.html) 2022-03-18

Family

ID=65955185

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020550823A Pending JP2021518414A (ja) 2018-03-19 2019-03-19 細菌株を含む組成物
JP2020550598A Pending JP2021518129A (ja) 2018-03-19 2019-03-19 組成物
JP2023072015A Pending JP2023100747A (ja) 2018-03-19 2023-04-26 組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020550598A Pending JP2021518129A (ja) 2018-03-19 2019-03-19 組成物
JP2023072015A Pending JP2023100747A (ja) 2018-03-19 2023-04-26 組成物

Country Status (25)

Country Link
US (3) US11419931B2 (cg-RX-API-DMAC7.html)
EP (3) EP4046644A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021518414A (cg-RX-API-DMAC7.html)
KR (2) KR102578117B1 (cg-RX-API-DMAC7.html)
CN (2) CN112004543A (cg-RX-API-DMAC7.html)
AU (2) AU2019239048B2 (cg-RX-API-DMAC7.html)
BR (2) BR112020019008A2 (cg-RX-API-DMAC7.html)
CA (2) CA3094297A1 (cg-RX-API-DMAC7.html)
CY (1) CY1125104T1 (cg-RX-API-DMAC7.html)
DK (1) DK3768284T3 (cg-RX-API-DMAC7.html)
ES (1) ES2908826T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220368T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058151T2 (cg-RX-API-DMAC7.html)
IL (2) IL277422A (cg-RX-API-DMAC7.html)
LT (1) LT3768284T (cg-RX-API-DMAC7.html)
MA (1) MA52128A (cg-RX-API-DMAC7.html)
MD (1) MD3768284T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020009733A (cg-RX-API-DMAC7.html)
PL (1) PL3768284T3 (cg-RX-API-DMAC7.html)
RS (1) RS63090B1 (cg-RX-API-DMAC7.html)
SG (2) SG11202009254YA (cg-RX-API-DMAC7.html)
SI (1) SI3768284T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200111T1 (cg-RX-API-DMAC7.html)
TW (2) TW202003001A (cg-RX-API-DMAC7.html)
WO (2) WO2019180051A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains
WO2021113500A2 (en) * 2019-12-03 2021-06-10 Board Of Regents, The University Of Texas System Combination therapies for the treatment of cancer
EP4161541A4 (en) * 2020-06-09 2024-09-11 Flagship Pioneering Innovations VI, LLC PHYSIOLOGICALLY ACCEPTABLE COMPOSITIONS CONTAINING MICROORGANISMS OR MICROBIAL PRODUCTS
KR102461645B1 (ko) * 2020-10-20 2022-11-01 전남대학교산학협력단 플라젤린 융합 단백질을 포함하는 비알코올성 지방간질환 또는 대사증후군 예방 또는 치료용 조성물
EP4384194A4 (en) * 2021-10-08 2025-07-16 Univ Iowa State Res Found Inc USE OF DOPAMINE-PRODUCING PRODUCTS TO INCREASE VACCINE EFFECTIVENESS
CN113999923B (zh) * 2021-11-25 2024-05-14 上海金翌生物科技有限公司 小柳-原田综合症标志微生物及其应用
CN115287243B (zh) * 2022-04-15 2023-06-06 集美大学 一株变形假单胞菌flgK基因沉默菌株及其构建方法
JPWO2024096122A1 (cg-RX-API-DMAC7.html) * 2022-11-04 2024-05-10
KR102878250B1 (ko) 2023-01-11 2025-10-31 서울대학교산학협력단 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
JPH08259450A (ja) 1995-03-17 1996-10-08 Nichinichi Seiyaku Kk インターフェロン産生増強剤
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US20080025977A1 (en) 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
JP2007116991A (ja) 2005-10-28 2007-05-17 Eternal Light General Institute Inc 機能性食品
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
EP1958647A1 (en) 2007-02-15 2008-08-20 Helmholtz-Zentrum für Infektionsforschung GmbH Pharmaceutical composition with bacteria for tumor treatment
EP2133092B1 (en) 2007-03-19 2015-12-09 Morishita Jintan Co., Ltd. Oral vaccine
JP2011519834A (ja) * 2008-04-25 2011-07-14 インスティチュート フォー システムズ バイオロジー フラジェリンポリペプチドワクチン
EP2486134B1 (en) * 2009-10-06 2014-01-08 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
EP2663367A4 (en) 2011-01-10 2014-08-06 Cleveland Biolabs Inc USE OF GREAT-SIMILAR RECEPTOR AGONISTS FOR THE TREATMENT OF CANCER
EP2731572B1 (en) 2011-07-13 2021-04-07 Pharmaxis Ltd. Improvements relating to delivery devices
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
ES2408279B1 (es) 2011-12-15 2014-09-09 Universidad De Las Palmas De Gran Canaria Bacteria acido láctica probiótica
FR2989002B1 (fr) 2012-04-10 2015-05-15 Beepratte Lab Compositions a base de probiotiques et d'un complexe beepollen/argile, leur preparation et leurs utilisations en nutrition et therapeutique
WO2014043593A2 (en) 2012-09-13 2014-03-20 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10480002B2 (en) * 2014-02-12 2019-11-19 Transalgae Israel Ltd. Algal based edible vaccines
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41013A (fr) * 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520502D0 (en) * 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41708A (fr) * 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
KR102563191B1 (ko) 2017-07-05 2023-08-02 에벨로 바이오사이언시즈, 인크. 비피도박테리움 애니멀리스 ssp. 락티스를 이용한 암 치료 조성물 및 방법
BR112020002212A2 (pt) 2017-08-10 2020-07-28 4D Pharma Research Limited composições compreendendo cepas bacterianas
WO2019180051A1 (en) 2018-03-19 2019-09-26 4D Pharma Research Limited Compositions comprising bacterial strains

Similar Documents

Publication Publication Date Title
JP2018199695A5 (cg-RX-API-DMAC7.html)
JP6701276B2 (ja) 細菌株を含む組成物
Matsuzaki et al. Modulating immune responses with probiotic bacteria
KR101914248B1 (ko) 박테리아 균주를 함유한 조성물
RU2020132171A (ru) Новая бифидобактерия, характеризующаяся различными функциями, и ее применение
HRP20220578T1 (hr) Pripravci koji sadrže bakterijske sojeve
Cong et al. Comparative efficacy of a multi-epitope DNA vaccine via intranasal, peroral, and intramuscular delivery against lethal Toxoplasma gondii infection in mice
CN103547276A (zh) 保护免受上呼吸道感染的非复制性益生菌微生物
CN106795482B (zh) 允许在营养不良的情况下促进人和动物的幼年生长的乳杆菌组合物
CN104224851B (zh) 动物双歧杆菌乳酸亚种CGMCC No.9273的应用
KR102578117B1 (ko) 조성물
Jun et al. Bystander-mediated stimulation of proteolipid protein-specific regulatory T (Treg) cells confers protection against experimental autoimmune encephalomyelitis (EAE) via TGF-β
JP2018522041A5 (cg-RX-API-DMAC7.html)
JP2021502391A5 (cg-RX-API-DMAC7.html)
Fu et al. Effects of different CpG oligodeoxynucleotides with inactivated avian H5N1 influenza virus on mucosal immunity of chickens
CA2409813C (en) Compositions and methods for treatment of mucosal infections
JP2014139185A5 (cg-RX-API-DMAC7.html)
JP2021534089A5 (cg-RX-API-DMAC7.html)
EP4178597A2 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
JP6713751B2 (ja) 抗原に対する特異的な細胞傷害性t細胞(ctl)及び抗体産生を増強させる方法
Molinelli et al. Biologic therapy in psoriasis (Part II): efficacy and safety of new treatment targeting IL23/IL-17 pathways
CN111686107B (zh) 化合物plx51107用于制备预防或治疗非洲猪瘟药物的新用途
WO2017222295A1 (ko) 김치 및 된장 유래 젖산균을 유효성분으로 포함하는 인플루엔자 바이러스 예방 및 치료용 조성물
RU2008142140A (ru) Противотуберкулезная вакцина
Vojdani et al. Regulatory T cells, a potent immunoregulatory target for CAM researchers: modulating allergic and infectious disease pathology (II)